Search Results
Your search for L matches 3307 pages
Showing 301 - 350Investigators Highlight Characteristics Potentially Linked to Improved CAR T-Cell Therapy Outcomes in Large B-Cell Lymphoma
Investigators have assessed whether specific tumor characteristics were associated with improved outcomes in patients with large B-cell lymphoma who received chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Locke et al in Nature Medicine. The findings may...
American Cancer Society Annual Report Shows Cancer Mortality Still Declining, but Cancer Incidence Is Projected to Top 2 Million
Although overall cancer mortality has continued to decline, resulting in over 4 million fewer deaths in the United States since 1991, increasing incidence for 6 of the top 10 cancers pushed the projected number of new diagnoses to over 2 million (2,001,140) for the first time, according to the...
Obesity and a Precursor of Multiple Myeloma
Patients with obesity may be more likely to have monoclonal gammopathy of undetermined significance, according to a recent study published by Lee et al in Blood Advances. Background Monoclonal gammopathy of undetermined significance—a benign hematologic condition characterized by an abnormal...
Attitudes Toward Climate Change May Impact Cancer Screening Behavior
Investigators have discovered that individuals who view climate change as a health threat may be more likely to undergo cancer screening, according to a recent study published by Qian et al in the Journal of the National Cancer Institute. The recent findings supported the development of public...
Expert Point of View: Carlos L. Arteaga, MD
Carlos L. Arteaga, MD, commented on the findings of the PREFERABLE-EFFECT trial: “This is a wonderful study about what has been obvious to all of us—exercise improves quality of life. Most oncologists probably recommend it, but not necessarily in the structured and rigorous way this study did. We...
Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust Activity in Refractory Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...
All Adult Oncologists Are Geriatric Oncologists
The data developed over the past few years have overwhelmingly favored geriatric assessment as part of the routine care for older patients with cancer. It has become the standard of care. ASCO has recently published a Practical Geriatric Assessment to aid in the implementation of this vital...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
BEATcc Trial: Atezolizumab-Based Regimen Improves Outcomes in First-Line Setting for Advanced Cervical Cancer
In patients with recurrent or metastatic cervical cancer, the addition of the PD-L1–inhibiting monoclonal antibody atezolizumab to first-line chemotherapy plus the angiogenesis inhibitor bevacizumab significantly improved all efficacy outcomes and yielded a median overall survival that exceeded 2.5 ...
Recipients of 2023 Susan G. Komen Breast Cancer Awards Honored
Susan G. Komen presented its 2023 Breast Cancer Awards to four physician-scientists and one research advocate for their contributions to advancing breast cancer discoveries and improving patient outcomes. The five recipients were recognized at the Susan G. Komen Breast Cancer Awards event in San...
Understanding the Treatment Options for PD-1–Refractory Melanoma
For the treatment of advanced melanoma that is refractory to anti–PD-1 antibodies, there is no standard approach. The various options, with a look to the future, were discussed by Melinda L. Yushak, MD, MPH, Assistant Professor of Hematology and Oncology at Emory University School of Medicine, at...
Risk Model May Accurately Predict Aromatase Inhibitor Nonadherence
A novel risk model may be effective at using baseline sociodemographic and financial measures to predict the risk of long-term aromatase inhibitor nonadherence among patients with breast cancer, according to new findings presented by Hershman et al at the 2023 San Antonio Breast Cancer Symposium...
Highlights From the ESMO Congress 2023
The European Society for Medical Oncology (ESMO) Congress 2023 held in Madrid reported out several eagerly awaited and potentially practice-changing trials, bringing forward promising new combination strategies in the targeted and immunotherapy space, and put to the test selective agents against...
Adding Checkpoint Inhibition to Perioperative Chemotherapy Boosts Pathologic Complete Response Rates in Gastric Cancers
The addition of immune checkpoint inhibitors to perioperative chemotherapy for gastric and gastroesophageal junction cancers boosts pathologic complete response rates, but the ultimate impact on clinical outcomes remains unclear, according to interim analyses from two phase III trials presented at...
CodeBreaK 300: Sotorasib Plus Panitumumab of Benefit in KRAS-Mutated Metastatic Colorectal Cancer
The combination of sotorasib and panitumumab significantly improved progression-free survival compared with standard treatment in patients with chemotherapy-refractory metastatic colorectal cancer with KRAS G12C mutations, the phase III CodeBreaK 300 trial has shown. The KRAS G12C inhibitor...
Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows ‘Robust’ Activity in Refractory Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...
Highlights From the 2023 World Conference on Lung Cancer
The management of lung cancer and other thoracic malignancies has evolved significantly over the past decade. Thanks to many scientific advancements in the field, new therapeutic options, and improvements in screening and early detection, more patients are being cured, and many others are living...
Cardiac Imaging and Biomarkers for Patients Receiving Cancer Treatment: What Oncologists Need to Know
For many years, researchers around the world have been exploring the connections between cancer treatments and the heart—better known as cardio-oncology. However, many oncologists may be less familiar with this emerging field and what they might need to know in terms of heart health to keep their...
Updates in Lower-Risk Myelodysplastic Syndromes/Neoplasms
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that are characterized by ineffective hematopoiesis, resulting in cytopenias, and they carry a risk of progression to acute myeloid leukemia (AML). In 2022, the fifth edition of the World Health ...
ASTRUM-004: Serplulimab Plus Chemotherapy as First-Line Treatment of Advanced Squamous Non–Small Cell Lung Cancer
A novel treatment approach to squamous non–small cell lung cancer (NSCLC) may improve the prognosis for patients with previously limited treatment options, according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 Findings from ...
ASCO Rapid Recommendation Update Cautions Against Triplet Therapy for Metastatic Clear Cell RCC
An ASCO Rapid Recommendation Update advises oncologists to avoid the use of triple combination therapy for the management of metastatic clear cell renal cell carcinoma (RCC).1 The new guidance, which updates recommendations from the original 2022 guideline, reflects findings from a phase III,...
AACR Annual Cancer Progress Report Highlights Scientific Advances Against Cancer, Challenges and Opportunities Ahead
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in prevention and early detection, has led to a 33% reduction in cancer...
Vitamin D Supplements May Help Reduce Chemotherapy-Induced Peripheral Neuropathy
Investigators have found that patients with breast cancer who have insufficient levels of vitamin D prior to initiating treatment with paclitaxel may be more likely to experience peripheral neuropathy, according to a recent study published by Chen et al in JNCCN–Journal of the National...
Advancing Clinical Research on Ovarian Cancer and Overcoming Gender Inequity in Low- and Middle-Income Countries
The management of ovarian cancer remains challenging within health-care systems worldwide. Recently, clinical and translational research on ovarian cancer has led to promising advances that have improved the survival outcomes of women diagnosed with this aggressive gynecologic cancer. These...
Adding HIPEC to Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases
As reported in the Journal of Clinical Oncology by Rau et al, the German phase III GASTRIPEC-I trial showed no improvement in overall survival with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery in patients with gastric cancer and synchronous peritoneal...
Cardiovascular Disease and Cancer: A Reciprocal Relationship?
More attention is being paid to the topic of cardio-oncology, where the focus is on patients with cancer who may be at risk for developing cardiovascular diseases as a result of anticancer treatments. However, a less well-known but related clinical area is now garnering some interest. Referred to...
Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities
It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
Dendritic Cell Vaccine Plus Stem Cell Transplant for Multiple Myeloma
Although the development of new therapies for multiple myeloma has significantly improved response rates and outcomes for patients with the blood cancer, most patients eventually relapse, including those who initially achieved remission. A phase I study is investigating whether a dendritic cell...
The New Era of Perioperative Therapy in Non–Small Cell Lung Cancer
Recent developments in surgery and therapeutics are changing the perioperative approach to non–small cell lung cancer (NSCLC). These advances were discussed at the 2023 Debates and Didactics in Hematology and Oncology conference, sponsored by Emory University, by Jennifer W. Carlisle, MD, Assistant ...
Liquid Biopsies May Be Predictive of Cancer Recurrence Following Chemoradiation in Patients With Cervical Cancer
Two liquid biopsy tests designed to detect the human papillomavirus (HPV) in the blood may accurately identify patients at high risk of cervical cancer recurrence following the completion of chemoradiation, according to new findings presented by Han et al at the 2023 American Society for Radiation...
Oral Health May Be Linked to Survival in Patients With Head and Neck Squamous Cell Carcinoma
Investigators have revealed that oral health may be associated with survival in patients with head and neck squamous cell carcinoma, according to a novel study published by Tasoulas et al in the Journal of the National Cancer Institute. Background While survival has improved during the past decades ...
Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma
The management of sarcoma presents several challenges because of its rarity and diverse subtypes, making accurate diagnosis and specialized treatment crucial. A multidisciplinary approach involving various experts from different cancer specialties is the optimal strategy to improve survival and...
Surgical Oncologist Héber Salvador, MD, PhD, Offers an Inside Look at Cancer Care in Brazil, Complete With Its Diversity and Inequities
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, the Jerald L. & Carolynn J. Varner Professor of Surgical Oncology & Global Health at the University of Nebraska Medical Center, Omaha, spoke with Héber Salvador, MD, PhD,...
ASCO Releases Rapid Recommendation Update on Use of Olanzapine to Treat Cancer-Related Cachexia
ASCO recently released a new rapid recommendation update that addresses the use of olanzapine to treat cancer-related cachexia, a topic originally addressed in its 2020 guideline on the management of cancer cachexia in adults with advanced cancer.1,2 At that time, there was insufficient evidence to ...
ASTRO Names FASTRO Recipients for 2023
A total of 29 distinguished members of the American Society for Radiation Oncology (ASTRO) have been named Fellows of ASTRO. The ASTRO Fellow designation, FASTRO, honors individuals who have contributed significantly to the Society through committee work, other volunteer service, and to the field...
More on Renal Cell Carcinoma From ASCO 2023: Focus on Atezolizumab Plus Cabozantinib vs Cabozantinib Alone
The addition of the monoclonal antibody atezolizumab to the tyrosine kinase inhibitor cabozantinib failed to improve progression-free survival and overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma (previously treated with an immune checkpoint inhibitor) in the...
Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting
The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...
Understanding the Treatment of Waldenström’s Macroglobulinemia
Waldenström’s macroglobulinemia is a rare and incurable low-grade B-cell lymphoproliferative disease defined by specific genotypic subtypes that have implications for treatment response and long-term outcomes. Treatment—and there is no established standard—is mainly focused on controlling symptoms...
First-Line Pembrolizumab Plus Lenvatinib Active in Advanced Non–Clear Cell Renal Cell Carcinoma
In a phase II trial (KEYNOTE-B61) reported in The Lancet Oncology, Laurence Albiges, MD, PhD, of Gustave Roussy, Paris–Saclay University, Villejuif, France, and colleagues found that first-line pembrolizumab plus lenvatinib produced durable responses in patients with advanced non–clear cell renal...
Effect of Diet and Exercise Intervention on Chemotherapy Dose Intensity, Response Rate Among Patients With Breast Cancer
In the LEANer study, reported in the Journal of Clinical Oncology by Tara Sanft, MD, and colleagues, researchers found that an exercise and nutrition intervention did not improve relative dose intensity (RDI) among patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer, but did...
Accuracy of IASLC's 2009 Database for Pleural Mesothelioma Staging
Researchers have validated the accuracy of the International Association for the Study of Lung Cancer’s (IASLC) 2009 pleural mesothelioma database, with these findings presented by Wolf et al at the IASLC 2023 World Conference on Lung Cancer (Abstract MA17.04). Background Pleural mesothelioma often ...
AACR Issues Annual Cancer Progress Report
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in cancer prevention and early detection, has led to a 33% reduction in cancer...
Expert Point of View: Barbara Burtness, MD
Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, featured the CONTINUUM study at the head and neck cancer session on Highlights of the Day during the 2023 ASCO Annual Meeting. She noted the study’s premise...
CONTINUUM: In Locally Advanced Nasopharyngeal Cancer, Addition of Sintilimab to Chemoradiotherapy Offers Benefit
The addition of the PD-1 inhibitor sintilimab to standard induction chemotherapy and chemoradiotherapy resulted in a significant improvement in 3-year event-free survival, a manageable safety profile, and comparable quality of life in high-risk, locally advanced nasopharyngeal carcinoma vs standard ...
Head and Neck Cancers 2022–2023 Almanac
Head and neck cancers comprise approximately 4% of all new cancer diagnoses globally and represent approximately 110,000 new cancer diagnoses and 17,000 cancer deaths annually in the United States. Head and neck cancers are a heterogenous group of malignancies where prognosis and treatment varies...
Incremental Gains Toward Better Outcomes in Small Cell Lung Cancer
Novel treatments beyond the current chemoimmunotherapies are offering more treatment options in small cell lung cancer (SCLC), though real breakthroughs remain elusive, according to Ticiana Leal, MD, Associate Professor in the Department of Hematology and Medical Oncology, Emory University School...
There’s an App for That: Digital Health Solutions for Treating Insomnia in Cancer Survivors
Guest Editor’s Note: Insomnia is common in patients with cancer and cancer survivors, and it has significant negative consequences. Cognitive behavior therapy for insomnia (CBT-I) is an effective approach for managing insomnia but is not easily available to many patients. In this installment of The ...
Phase III Trial Reports Chemoimmunotherapy Is Superior to Chemotherapy Alone in Malignant Pleural Mesothelioma
Patients with malignant pleural mesothelioma who were treated with a chemoimmunotherapy regimen containing the immune checkpoint inhibitor pembrolizumab experienced significantly improved overall survival compared with those treated with chemotherapy alone, with acceptable tolerability, according...
